A real-world study to evaluate the safety and efficacy of three injectable neurokinin-1 receptor antagonist formulations for the prevention of chemotherapy-induced nausea and vomiting in cancer patients

BACKGROUND: Three different injectable neurokinin-1 (NK-1) receptor antagonist formulations (CINVANTI® [C] vs. intravenous Emend® [E] vs. generic formulations of fosaprepitant [GFF]) were compared with respect to nausea and vomiting control, use of rescue therapy, and the development of infusion rea...

Descripción completa

Detalles Bibliográficos
Autores principales: Dranitsaris, George, Moezi, Mehdi, Dobson, Kate, Phelan, Robert, Blau, Sibel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213362/
https://www.ncbi.nlm.nih.gov/pubmed/35499619
http://dx.doi.org/10.1007/s00520-022-07082-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9213362/
https://www.ncbi.nlm.nih.gov/pubmed/35499619
http://dx.doi.org/10.1007/s00520-022-07082-7

Ejemplares similares